Pre-amplified gene expression levels of EpCAM and CK19 exhibited significantly higher prevalence in metastatic BC when compared with early BC (EpCAM: 31.3% vs. 7.3%; CK19: 21.1% vs. 2.4%). This evidence concerns the gene KRT19 and breast cancer.